Naples Laser & Skin

Molecular Profile

Tirzepatide
(Mounjaro / Zepbound)

Chemical formula	`C₂₂₂H₃₃₄N₅₄O₉₁`
Class	39-amino-acid synthetic peptide C20 fatty-diacid modified
Molecular weight	≈ 4,813.5 g/mol
Form	Subcutaneous injectable (prefilled pen or vial)
Half-life	≈ 5 days — supports once-weekly dosing
Origin	Developed by Eli Lilly; engineered from native GIP sequence with a fatty acid chain enabling albumin-binding and extended circulation

HOW IT WORKS

Tirzepatide binds and activates two incretin receptors — GIP and GLP-1 — simultaneously, a dual mechanism unique among approved agents. This slows gastric emptying, promotes satiety signaling in the brain, and enhances glucose-dependent insulin secretion while suppressing glucagon. The combined action produces greater effects on blood sugar and body weight than single-pathway GLP-1 agonists.

‍

WHAT TO EXPECT

Type 2 diabetes management (branded Mounjaro)
Chronic weight management (branded Zepbound)
Emerging research: sleep apnea, cardiometabolic risk reduction

BEFORE YOU START

First and only approved dual GIP/GLP-1 co-agonist — distinguishes it from single-target GLP-1s like semaglutide
Fatty-diacid side chain enables reversible albumin binding, extending its half-life for weekly dosing
Supplied as a clear, colorless-to-slightly-yellow solution in prefilled pens